The NM_000152.5:GAA:c.1828G>A variant in GAA is a missense variant predicted to cause substitution of Ala by Thr at amino acid 610 (p.Ala610Thr). Two patients with this variant have been reported in the literature (PMID: 32504392, 35775064). However, because the diagnosis of Pompe disease was unclear for both patients, neither PP4 nor PM3 was applied. One of these patients, a 4-year-old girl with IOPD identified as homozygous for GAA:c.1828G>A, was also diagnosed with congenital myasthenia syndrome type 5. Because her symptoms, which included bradycardia, poor suckling, respiratory distress, respiratory failure, subglottic stenosis, and tachypnea, could be related to congenital myasthenia syndrome and not Pompe disease, and GAA activity was unavailable, this data was not used as evidence to support pathogenicity of the variant. Another individual was reported to be compound heterozygous for c.1828G>A and c.1966-1968del, but clinical information regarding the presence or absence of clinical symptoms of Pompe disease, and GAA activity was unavailable. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00017 (1/5976 alleles) in the Other population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.641 which is neither above nor below the thresholds predicting a damaging (>0.7) or benign (<0.5) impact on GAA function (neither PP3 nor BP4 is met), and the computational splicing predictor SpliceAI gives a score of 0.00 for donor/acceptor loss suggesting that the variant has no impact on splicing. Another missense variant c.1829C>T (p.Ala610Val) in the same codon has been reported (PMID: 21484825, 17643989). However, this variant has not yet met the criteria to be classified as pathogenic or likely pathogenic by the ClinGen LSD VCEP (PM5 not met). There is a ClinVar entry for this variant (Variation ID: 282242, 2 star review status) with 5 submitters classifying the variant as Uncertain significance and 1 submitter classifying it as Pathogenic. In summary, this variant meets the criteria to be classified as Uncertain significance for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (specifications Version 2.0): PM2_Supporting. (Classification approved by the ClinGen LSD VCEP on Oct. 18, 2022).